Noticias de AIM_US

Noticias del mercado

Últimas noticias sobre AIM_US — 82 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AIM_US ✕ 82 resultados
22/04/2026 AIM_US — tayninh.gov.vn
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Most Watched Stocks
22/04/2026 AIM_US — sonla.gov.vn ES ← EN
AIM ImmunoTech Inc. (AIM) registra una pérdida mayor de lo esperado en el cuarto trimestre de 2025, pero las acciones suben modestamente en las operaciones de hoy. - Acciones más observadas

AIM ImmunoTech Inc. (AIM) registra una pérdida mayor de lo esperado en el cuarto trimestre de 2025, pero las acciones suben modestamente en las operaciones de hoy. - Acciones más…

18/04/2026 AIM_US — ADVFN
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
17/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
17/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
16/04/2026 AIM_US — GuruFocus ES ← EN
AIM ImmunoTech (AIM) avanza en los planes de tratamiento del cáncer de páncreas
16/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer
16/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
16/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
16/04/2026 AIM_US — ChartMill
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
16/04/2026 AIM_US — GlobeNewswire
AIM ImmunoTech Enters Pivotal Value Inflection Phase with
15/04/2026 AIM_US — Bitget ES ← EN
AIM ImmunoTech Inc. anuncia que su fármaco principal Ampligen® ha alcanzado un punto de inflexión de valor crítico en el campo del tratamiento del cáncer de páncreas.
15/04/2026 AIM_US — Bitget
AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment.
13/04/2026 AIM_US — Quiver Quantitative
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment
13/04/2026 AIM_US — GlobeNewswire
AIM ImmunoTech Provides Routine Update on Annual Filings
13/04/2026 AIM_US — Bitget ES ← EN
AIM ImmunoTech proporciona actualización de rutina sobre las presentaciones anuales
13/04/2026 AIM_US — Stock Titan
Why AIM had to disclose a going concern note in its 2025 audit
10/04/2026 AIM_US — Investing.com
AIM ImmunoTech amends equity distribution agreement to remove share sale limit
10/04/2026 AIM_US — GuruFocus
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News
10/04/2026 AIM_US — Stock Titan
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales

Página 1 de 5

keyboard_arrow_up